PMN: Interim trial data show zero ARIA-E and strong biomarker response for a novel Alzheimer's antibody
A novel antibody therapy for Alzheimer's demonstrated strong interim safety and promising biomarker engagement in a large phase I-B trial, with zero ARIA-E cases and a 15% decline in p-tau217. Top-line results are expected in Q1 2027, supported by robust funding and a differentiated technology plat…